Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Phase 3 Studies Show Kyprolis (Carfilzomib) Extends Progression Free Survival for Relapsed/Refractory Myeloma - HealthTree for Myeloma
August 11, 2014 Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myel
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma ( ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Cancers | Free Full-Text | Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Carfilzomib in multiple myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® ( carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Clinical Challenges in Patients With Relapsed/Refractory Multiple Myeloma (Transcript)
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Second Phase 3 Study Shows KYPROLIS Regimen Improves Overall Survival in Patients with Relapsed MM | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Amgen presents new data for Kyprolis in multiple myeloma at EHA
Carfilzomib in multiple myeloma
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Relapsed and Refractory Myeloma - ppt video online download
Carfilzomib in multiple myeloma
PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III
